Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

Abstract We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naïve nAMD associated with typ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hidetaka Matsumoto, Junki Hoshino, Ryo Mukai, Kosuke Nakamura, Hideo Akiyama
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a17792b82aab45309e696c14472efc0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a17792b82aab45309e696c14472efc0a
record_format	dspace
spelling	oai:doaj.org-article:a17792b82aab45309e696c14472efc0a2021-12-02T11:45:04ZShort-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy10.1038/s41598-021-86014-72045-2322https://doaj.org/article/a17792b82aab45309e696c14472efc0a2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86014-7https://doaj.org/toc/2045-2322Abstract We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naïve nAMD associated with type 1 CNV. Three monthly injections of brolucizumab were completed in 36 eyes (85.7%). In those cases, best-corrected visual acuity (BCVA) was 0.24 ± 0.27 at baseline and improved significantly to 0.12 ± 0.23 after 3 months (P < 0.001). Central macular thickness was 301 ± 110 µm at baseline and decreased significantly to 160 ± 49 µm after 3 months (P < 0.001). Dry macula was achieved in 34 eyes (94.4%) after the loading phase. Central choroidal thickness was 264 ± 89 µm at baseline and decreased significantly to 223 ± 81 µm after 3 months (P < 0.001). Indocyanine green angiography after the loading phase revealed complete regression of polypoidal lesions in 15 of the 19 eyes (78.9%) with polypoidal lesions. Non-infectious intraocular inflammation (IOI) was observed in 8 of 42 eyes (19.0%) during the loading phase, while showing amelioration in response to combination therapy with topical and subtenon injection of steroids. In these eyes, BCVA after 3 months had not deteriorated as compared to that at baseline. These results indicate that loading phase treatment with intravitreal brolucizumab might be effective for improving visual acuity and reducing exudative changes in eyes with nAMD associated with type 1 CNV. Moreover, polypoidal lesions appear to frequently regress after this treatment. However, we must monitor patients carefully for brolucizumab-related IOI, and administer steroid therapy promptly.Hidetaka MatsumotoJunki HoshinoRyo MukaiKosuke NakamuraHideo AkiyamaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hidetaka Matsumoto Junki Hoshino Ryo Mukai Kosuke Nakamura Hideo Akiyama Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
description	Abstract We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naïve nAMD associated with type 1 CNV. Three monthly injections of brolucizumab were completed in 36 eyes (85.7%). In those cases, best-corrected visual acuity (BCVA) was 0.24 ± 0.27 at baseline and improved significantly to 0.12 ± 0.23 after 3 months (P < 0.001). Central macular thickness was 301 ± 110 µm at baseline and decreased significantly to 160 ± 49 µm after 3 months (P < 0.001). Dry macula was achieved in 34 eyes (94.4%) after the loading phase. Central choroidal thickness was 264 ± 89 µm at baseline and decreased significantly to 223 ± 81 µm after 3 months (P < 0.001). Indocyanine green angiography after the loading phase revealed complete regression of polypoidal lesions in 15 of the 19 eyes (78.9%) with polypoidal lesions. Non-infectious intraocular inflammation (IOI) was observed in 8 of 42 eyes (19.0%) during the loading phase, while showing amelioration in response to combination therapy with topical and subtenon injection of steroids. In these eyes, BCVA after 3 months had not deteriorated as compared to that at baseline. These results indicate that loading phase treatment with intravitreal brolucizumab might be effective for improving visual acuity and reducing exudative changes in eyes with nAMD associated with type 1 CNV. Moreover, polypoidal lesions appear to frequently regress after this treatment. However, we must monitor patients carefully for brolucizumab-related IOI, and administer steroid therapy promptly.
format	article
author	Hidetaka Matsumoto Junki Hoshino Ryo Mukai Kosuke Nakamura Hideo Akiyama
author_facet	Hidetaka Matsumoto Junki Hoshino Ryo Mukai Kosuke Nakamura Hideo Akiyama
author_sort	Hidetaka Matsumoto
title	Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
title_short	Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
title_full	Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
title_fullStr	Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
title_full_unstemmed	Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
title_sort	short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a17792b82aab45309e696c14472efc0a
work_keys_str_mv	AT hidetakamatsumoto shorttermoutcomesofintravitrealbrolucizumabfortreatmentnaiveneovascularagerelatedmaculardegenerationwithtype1choroidalneovascularizationincludingpolypoidalchoroidalvasculopathy AT junkihoshino shorttermoutcomesofintravitrealbrolucizumabfortreatmentnaiveneovascularagerelatedmaculardegenerationwithtype1choroidalneovascularizationincludingpolypoidalchoroidalvasculopathy AT ryomukai shorttermoutcomesofintravitrealbrolucizumabfortreatmentnaiveneovascularagerelatedmaculardegenerationwithtype1choroidalneovascularizationincludingpolypoidalchoroidalvasculopathy AT kosukenakamura shorttermoutcomesofintravitrealbrolucizumabfortreatmentnaiveneovascularagerelatedmaculardegenerationwithtype1choroidalneovascularizationincludingpolypoidalchoroidalvasculopathy AT hideoakiyama shorttermoutcomesofintravitrealbrolucizumabfortreatmentnaiveneovascularagerelatedmaculardegenerationwithtype1choroidalneovascularizationincludingpolypoidalchoroidalvasculopathy
_version_	1718395300684496896

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

Ejemplares similares